25.10.2014 Views

Rapporto annuale 2007 - Istituto di Ricerche Farmacologiche Mario ...

Rapporto annuale 2007 - Istituto di Ricerche Farmacologiche Mario ...

Rapporto annuale 2007 - Istituto di Ricerche Farmacologiche Mario ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

IRFMN<br />

COLLABORAZIONI INTERNAZIONALI<br />

European Me<strong>di</strong>cine Agency (EMEA)<br />

Karolinska Institute, Farmacologia Clinica, Dipartimento <strong>di</strong> Laboratory Me<strong>di</strong>cine, SE<br />

Università <strong>di</strong> Liverpool, Management School, Prescribing Research Group, UK<br />

Organizzazione Mon<strong>di</strong>ale della Sanità (Dipartimento dei Farmaci Essenziali e della Politica<br />

Farmaceutica)<br />

Association of South East Asian Nations (ASEAN)<br />

Ricerca & Pratica<br />

Dialogo sui Farmaci<br />

PRESENZA IN COMITATI EDITORIALI<br />

PRESENZA IN COMMISSIONI NAZIONALI E INTERNAZIONALI<br />

Commissione Tecnico Scientifica presso l'Agenzia Italiana del Farmaco (AIFA)<br />

Sottocommissione Procedure Comunitarie presso l'Agenzia Italiana del Farmaco (AIFA)<br />

Comitato Scientifico dell’Italian Horizon Scanning Project<br />

SELEZIONE PUBBLICAZIONI SCIENTIFICHE APPARSE<br />

NELL'ANNO <strong>2007</strong><br />

Garattini S, Bertele' V. Non-inferiority trials are unethical because they <strong>di</strong>sregard patients' interests. Lancet <strong>2007</strong>;<br />

370: 1875-1877<br />

Garattini S, Bertele' V. How can we regulate me<strong>di</strong>cines better? BMJ <strong>2007</strong>; 335: 803-805<br />

Barbui C, Cipriani A, Lintas C, Bertele' V, Garattini S. CNS drugs approved by the centralised European procedure:<br />

true innovation or dangerous stagnation? Psychopharmacology (Berl) <strong>2007</strong>; 190: 265-268<br />

Bertele' V, Buonocore C, Michelacci F, Vitocolonna M, Garattini S. Efficacy and safety of immunosuppressive drugs<br />

approved in EU through the centralised procedure. Eur J Clin Pharmacol <strong>2007</strong>; 63: 707-712<br />

Bertele' V, Banzi R, Capasso F, Tafuri G, Trotta F, Apolone G, Garattini S. Haematological anticancer drugs in<br />

Europe: any added value at the time of approval? Eur J Clin Pharmacol <strong>2007</strong>; 63: 713-719<br />

Bertele' V, Assisi A, Di Muzio V, Renzo D, Garattini S. New antirheumatic drugs: any real added value? A critical<br />

overview of regulatory criteria for their marketing approval. Eur J Clin Pharmacol <strong>2007</strong>; 63: 879-889<br />

Godman B, Haycox A, Bertele' V, Schwabe U. UK OFT pricing proposal - a necessity to fund new<br />

drugs or new in<strong>di</strong>cations. BMJ online 9 May <strong>2007</strong>. Available in URL from:<br />

http://www.bmj.com/cgi/eletters/334/7600/936#165136<br />

206<br />

RAPPORTO ATTIVITA’ <strong>2007</strong>

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!